Semnur Pharmaceuticals Separation Agreement Filing

Semnur Pharmaceuticals, Inc. filed an SEC 8-K exhibit containing a separation agreement for an individual whose employment ended March 13, 2026. The agreement states the person resigned from all positions and board roles effective the Separation Date.

If the agreement is signed and becomes effective and irrevocable no later than 60 days after the Separation Date, the individual receives continued base salary for six months at a rate of $1,250,000 per year, subject to withholding. The agreement also ends participation in the group health plan at month-end and provides eligibility to continue coverage under COBRA at the individual’s expense.

The filing states option vesting ceased as of the Separation Date and grants a 90-day extension to exercise vested options, with other compensation and benefits addressed under the agreement’s terms.